VirMedica Appoints John H. Johnson As Executive Chairman Of The Board Of Directors

PHILADELPHIA, Nov. 9, 2015 /PRNewswire/ -- VirMedica, the leader in providing e-access technology solutions designed to expedite patient access to biopharmaceutical products, today announced the appointment of John H. Johnson as executive chairman of the Company's Board of Directors, effectively immediately.

John H. Johnson is a recognized leader in the biopharmaceutical industry with more than 30 years of experience at leading global organizations, including Johnson & Johnson, Eli Lilly & Company, ImClone and Pfizer, Inc. He currently serves as chairman of Strongbridge Biopharma plc, and as a member of the board of directors of Cempra Pharmaceuticals, Inc., Histogenics Corporation, Portola Pharmaceuticals, Inc., and Sucampo Pharmaceuticals, Inc. He previously served as a member of the board of directors of Pharmaceutical Research and Manufacturers of America (PhRMA), the Health Section Governing Board of Biotechnology Industry Organizations (BIO), and BioNJ.

"VirMedica's proprietary portfolio of e-access platforms will fundamentally change the entire patient access ecosystem over the next several years," said John H. Johnson, executive chairman of VirMedica. "I am pleased to serve as executive chairman of VirMedica during such an exciting and transformative time in the Company's history, and look forward to leveraging my healthcare industry experience to help VirMedica realize its vision of expediting the patient journey to life-saving and enhancing therapies," Johnson added.

VirMedica also continues to strengthen its board of directors and executive leadership team with several recent appointments. Members of VirMedica's board of directors include Dean Erhardt, David Fitzgerald, David Golding and Garheng Kong, M.D., Ph.D., MBA. VirMedica's leadership team includes Dean Erhardt, James McGuire, Gregory R. Morris, John Roberts and Randall Rogers.

About VirMedica

VirMedica is an innovative holding company bringing together complementary businesses for the specific purpose of redefining the market access landscape for biopharmaceutical products.


Corporate & Media Relations

Stephen J. Henricks
VP, Marketing
[email protected]
+1 813-486-9484

Elixir Health Public Relations
Lindsay M. Rocco
[email protected]
+1 862-596-1304

To view the original version on PR Newswire, visit:

SOURCE VirMedica

Suggested Articles

German researchers uncovered 28 antibodies that neutralize COVID-19 and are working with Boehringer Ingelheim to advance them into clinical testing.

Oragenics is ending a phase 2 study of its oral mucositis drug, yanking its IND application and switching its focus to a COVID-19 vaccine.

The vehicle, which Blackstone claims is the largest life sciences private fund, has committed close to $1 billion to companies including Alnylam.